anti-b7-h4/anti-4-1bb bispecific antibody cln-418
anti-b7-h4/anti-4-1bb bispecific antibody cln-418: developed by 1 company · 1 clinical trial tracked.
anti-b7-h4/anti-4-1bb bispecific antibody cln-418 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could anti-b7-h4/anti-4-1bb bispecific antibody cln-418 → CGEM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) Patients with advanced solid tumors; targets cancers with hi… | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors
Primary endpoint: Proportion of subjects with dose-limiting toxicity (DLT)
Frequently asked questions
Who is developing anti-b7-h4/anti-4-1bb bispecific antibody cln-418?
anti-b7-h4/anti-4-1bb bispecific antibody cln-418 is being developed by Cullinan Therapeutics, Inc..
How many clinical trials involve anti-b7-h4/anti-4-1bb bispecific antibody cln-418?
BioSniper tracks 1 clinical trial involving anti-b7-h4/anti-4-1bb bispecific antibody cln-418.